Recombinant tissue plasminogen activator
Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
... Methods: In a prospective study, over a 55-month period, any patient at the hospital for whom stroke code had been activated was enrolled in the study. Data on demographic characteristics, stroke risk factors, admission ...
7
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
... How to cite this article: Muengtaweepongsa S, Prapa-Anantachai P, Dharmasaroja PA. Not only the sugar, early infarct sign, hyperDense middle cerebral artery, age, neurologic deficit score but also atrial fibrillation is ...
6
Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke
... Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke.. Florian Doepp* 1 , Wasiem Sanad 2 ,[r] ...
5
Infective Endocarditis Successfully Treated in Extremely Low Birth Weight Infants With Recombinant Tissue Plasminogen Activator
... with recombinant tissue plasminogen activator in addi- tion to prolonged antiinfective ...infants. Tissue plasminogen ac- tivator may play an important role when standard care ...
8
Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis
... Abstract: Low-toxicity magnetic nanocarriers (MNCs) composed of a shell of poly [aniline-co-N-(1-one-butyric acid) aniline] over a Fe 3 O 4 magnetic nanoparticle core were developed to carry recombinant ...
15
Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis
... heli2003new@ 126. com To cite: Guo Y, Yang Y, Zhou M, et al. Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue ...
6
Simultaneous Treatment with Intravenous Recombinant Tissue Plasminogen Activator and Endovascular Therapy for Acute Ischemic Stroke Within 3 Hours of Onset
... T he principal goal in treating acute ischemic stroke is rapid recanalization of occluded arteries by thrombolysis. Pa- tients transferred to a stroke center within 1 to 2 hours of onset might be fortunate in undergoing ...
6
Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD
... subretinal recombinant tissue plasminogen activator (rTPA) (125 µ g/mL) through a 41-gauge flexible translocation microcannula (DORC-dual bore BSS injection needle ...
5
Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator
... Background and purpose: Intravenous recombinant tissue plasminogen activator (tPA) at a dose of 0.9 mg/kg body weight is associated with a high hemorrhagic transformation (HT) rate. Low-dose ...
8
Ginkgo biloba extract and its diterpene ginkgolide constituents ameliorate the metabolic disturbances caused by recombinant tissue plasminogen activator in rat prefrontal cortex
... Although recombinant tissue plasminogen activator (rtPA) is a widely used therapy in patients with acute ischemic stroke, rtPA-induced toxicity or its adverse effects have been reported in our ...
18
Propagating Relationship of Cerebral Oximetric Volume and the Clinical Outcome of Recombinant Tissue Plasminogen Activator (r-TPA) Therapy on Acute Cerebral Ischemic Stroke Patients
... 26. Balucani C, Levine SR, Khoury JC, Khatri P, Saver JL, Broderick JP. Acute ischemic stroke with very early clinical improvement: a national institute of neurological disorders and stroke recombinant ...
8
A Review on Recombinant Tissue Plasminogen Activator: In Vitro Synthesis and Its Use in Treatment of Acute Ischemic Stroke
... vitro. Tissue plasmi- nogen activator (rtPA, Activase), in 1987 was the first recombinant therapeutic protein synthesised in CHO—a mammalian cell ...other recombinant proteins ...
6
Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction
... Keywords: tissue plasminogen activator (rTPA), vitreous body, macular hole, vitrectomy, epiretinal membrane, diabetic retinopathy.. Introduction.[r] ...
10
Recombinant Tissue Plasminogen Activator Treatment in Two Infants With Fulminant Meningococcemia
... Using scoring systems (Sinclair et al,2 Tesoro and Selbst,5 and Stiehm and Darnrosch38), shock, altered mental status, rapid onset of symptoms, a normal white blood cell count, and a nor[r] ...
7
Do Iodinated Contrast Agents Impair Fibrinolysis in Acute Stroke? A Systematic Review
... rtPA, recombinant tissue plasminogen activator; DIAS I, Desmoteplase in Acute Ishemic Stroke Trial; NINDS, National Institute of Neurological Disorders and ...
5
Intra Arterial Stroke Therapy: An Assessment of Demand and Available Work Force
... Patients with a National Institutes of Health Stroke Score NIHSS of less than 10 who are treated with intravenous recombinant tissue plasminogen activator rtPA have an 82% chance of a go[r] ...
6
Evaluation of an Intravenous Endovascular Strategy in Patients with Acute Proximal Middle Cerebral Artery Occlusion
... V recombinant tissue plasminogen activator therapy is the standard treatment for acute ischemic stroke within 4.5 hours of symptom onset.1 However, this therapeutic approach remains unsa[r] ...
6
Balloon Catheter Disruption of Middle Cerebral Artery Thrombus in Conjunction with Thrombolysis for the Treatment of Acute Middle Cerebral Artery Embolism
... using recombinant tissue plasminogen activator (rtPA) has been shown to be an effective treatment for the acute occlusion of the middle cere- bral artery ...
5
Safety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke
... Results: Thirty seven patients with acute ischemic stroke who treated with recombinant tissue plasminogen activator (r-TPA) were studied. There were hemorrhagic transformations in 9 (24%) ...
6
GLP-1 RECEPTOR ACTIVATION-BASED THERAPY; A PROMISING STRATEGY AGAINST ISCHEMIC STROKE
... of recombinant tissue plasminogen activator (rtpa) treatment in animal models of ischemic stroke (28, 29), The correlation between hyperglycemia and aggravated cerebral injury in stroke ...
6